Management


Ori Choshen

Ori Choshen

CEO

Ori has vast experience in investments, senior management, BusDev and entrepreneurship, in the areas of Tech & Life Science. He holds an LL.B degree, a B.A. in Philosophy (Cum Laude) from Tel Aviv University, and an MBA (Cum Laude) from the Solvay Business School in Brussels, Belgium.

As part of his position in VLX Ventures, Ori established, invested and mentored start-ups in several domains, including Pharma, Data and AI.

Prior to joining VLX Ventures in 2013:
• VP BusDev of Xenia Venture Capital
• Co-founder of Aniba, the first local web-site in the event planning category
• Director of BusDev with SanDisk, (NSDQ: SNDK), managed the Eco-System Group. Ori joined SanDisk as part of the company’s $1.6 Bn acquisition of M-Systems (NSDQ: FLSH) in 2006
• Director of BusDev and Marketing at M-Systems
• Member in Hutchison’s global handset group (Strategy, BusDev) and managed the Handset Department (Marketing) of Orange Israel (Hutchison’s subsidiary)
• Investment Manager in PFC, Orange’s VC subsidiary

Dr. Nadav Klein

Dr. Nadav Klein

CTO

Nadav holds vast and diversified experience as a technology expert and researcher in both industry and academia. He brings years of experience in building, managing, and nurturing technology driven teams and startups, in the Information Technology, Agtech, and Life Science industries.

Nadav’s keen interest and proficiency in Healthcare, Bioinformatics, and Artificial Intelligence applications allowed for a rich academic background, spanning a wide range of multifaceted research fields, most notably Computational Biology, Genomics, Bioinformatics, Precision Agriculture, Advanced Data Science, Robotics, Renewable Energy, and Precision Medicine. His unique abilities, combining technological expertise, deep science competence, and strong business skills, are exceptionally rare, even more so in the Venture Capital realm, constituting a significant asset to our portfolio companies.

Nadav holds both a PhD in Bioinformatics from the University of California-Davis (with honors and distinction), and a BSc in Bioinformatics from Tel Aviv University (magna cum laude). He shares his knowledge as a lecturer at the Interdisciplinary Center (IDC) Herzliya, Tel Aviv University, and the Technion

Eli Sorzon

Eli Sorzon

CFO

Eli Sorzon has 13 years experience in accounting and finance, mainly for large publicly traded hi-tech companies. He is a CPA and holds a bachelor’s degree in Business Administration from the College of Management Academic Studies Division.
Prior to joining Xenia in 2007:
• Manager with the accounting firm of Deloitte Brightman Almagor.
• Manager with Goldstein Sabo Tevet, a leading Tel Aviv accounting firm specializing in hi-tech companies traded on NASDAQ and TASE.

Prof. Ronit Satchi-Fainaro, Ph.D.

Prof. Ronit Satchi-Fainaro, Ph.D.

Advisory Board

Head, Cancer Research and Nanomedicine Laboratory
Chair, The Hermann and Kurt Lion Cathedra in Nanosciences and Nanotechnologies
Chair, Department of Physiology and Pharmacology
Sackler Faculty of Medicine, Tel Aviv University, Israel http://medicine.mytau.org/satchi-fainaro ronitsf@tauex.tau.ac.il

Prof. Ronit Satchi-Fainaro (Ph.D.) is a Full Professor at Tel Aviv University, where she is Head of the Cancer Research & Nanomedicine Laboratory; Chair of the Department of Physiology & Pharmacology at the Sackler Faculty of Medicine, and Chair of The Kurt and Herman Lion Cathedra in Nanosciences and Nanotechnologies. She previously served as President of The Israeli Controlled Release Society (CRS) (2010-2015) and Chair of IACUC of Tel Aviv University (2013-2017). She received her B.Pharm. from the Hebrew University in Jerusalem in 1995 and her Ph.D. (Summa Cum Laude) in Polymer Chemistry and Cancer Nanomedicine from the University of London in 1999 with Prof. Ruth Duncan. She then spent four years as Postdoctoral Research Fellow at Harvard University and Children’s Hospital Boston working with Prof. Judah Folkman on Vascular and Cancer Biology. In 2003, she was appointed Instructor in Surgery at Boston Children’s Hospital and Harvard Medical School. She joined Tel Aviv University in 2006. She serves on the Board of Directors of Teva Pharmaceutical Industries Ltd., Board of Governors of Tel Aviv University, member of the Scientific Advisory Board (SAB) of the Blavatnik Center for Drug Discovery, the Israel Cancer Association, the Hospital Universitari Vall d’Hebron – Institut de Recerca (VHIR, Barcelona, Spain), several VCs (VLX, etc.) and several Editorial Boards of Scientific Journals.
Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets interrupting tumor-host interactions. Her approach is followed by the design of highly-selective targeting molecules integrating biology, chemistry, medicine, bioinformatics and nanotechnology to selectively guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. She published more than 110 manuscripts, 12 book chapters, edited 2 books, is named inventor on 51 patents, some of which were licensed to pharmaceutical and Biotech companies. She was awarded numerous prestigious grants and prizes among them Fulbright, Rothschild, Wingate, Alon, Young Investigator Award of the European Association for Cancer Research, JULUDAN Prize for the Advancement of Technology in Medicine, and the 2013 Teva Pharmaceutical Industries Founders Award for the Discovery of new molecular mechanisms and targets that would lead to new therapeutic approaches. Her scientific achievements were acknowledged numerous times by inclusion in honorary lists by leading magazines (Forbes, Globes, The Marker 40/40, Calcalist, etc.). She was recently elected the next 2019 Chair of the Gordon Research Conference (GRC) on Cancer Nanomedicine, was awarded the 2018 Israel Cancer Research Foundation (ICRF) Professorship, was selected to represent Israel at the Biennale in Venice in 2016 on the Influence of Medicine on Architecture, and was awarded the European Research Council (ERC) Consolidator, Advanced and Proof of Concept (PoC) Grants.

Prof. Gabi Barabash MD, MPH

Prof. Gabi Barabash MD, MPH

Advisory Board

Former Head of The Tel-Aviv Sourasky Medical Center.
Director, Bench to Bedside Program, Weizmann Institute of Science, Rehovot.